For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ PNC-27
Illustration for PNC-27

THE PEPSRADAR ENCYCLOPEDIA

PNC-27

Experimental cancer-cell membrane research

Research topics · Sources checked 2026-10-04

Read the studies ↓

PNC-27 · KEY FACTS

Content updated · how dates work

Saved peptides

What is PNC-27?

PNC-27 is a laboratory peptide built from part of the p53 tumor-suppressor protein attached to a cell-penetrating sequence. It has been studied in cancer-cell cultures and animal models. It is not an approved or human-tested cancer treatment.

Biological role or research focus

Experimental cancer-cell membrane research.

One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.

Role reference: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Names you may encounter

p53-penetratin peptide

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Synthetic chimeric peptide: an HDM-2-binding segment of p53 joined to a membrane-penetrating sequence
Research focus
Experimental cancer-cell membrane research
Featured evidence
Cell study
Source check
October 4, 2026

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Quick answers

Is PNC-27 FDA approved?
No. No FDA-approved drug contains PNC-27. Source ↗
Is PNC-27 safe?
Experimental anticancer peptide with no published human safety studies. It kills cells by damaging their membranes, and its effects on normal tissue in the body are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is PNC-27 banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Cell experiments
StudyTypePopulation / model
Labeled PNC-27 in breast cancer and non-cancer breast cells (2010)Cell studyMCF-7 human breast cancer cells and untransformed MCF-10-2A breast epithelial cells in culture.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Cell study · 2010

Labeled PNC-27 in breast cancer and non-cancer breast cells

What did this publication test, and what did it find?

Population / model
MCF-7 human breast cancer cells and untransformed MCF-10-2A breast epithelial cells in culture.
Study design
The peptide carried a different fluorescent label at each end so investigators could track whether it stayed intact in the membranes of cancer and non-cancer cells over time.
Main finding
In the cancer cells, intact peptide collected in the membrane and the cells broke apart. In the non-cancer cells, the signal faded and the cells stayed alive. The authors concluded that the whole peptide, not its fragments, causes the membrane damage.
Limits & context
One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming PNC-27 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Search additional PubMed records ↗

Risks & interactions

Experimental anticancer peptide with no published human safety studies. It kills cells by damaging their membranes, and its effects on normal tissue in the body are unknown.

Human safety data: None

No published human safety or efficacy studies were found. Evidence comes from cell cultures, largely from one research group, in which cancer cells were damaged while the tested normal cells survived; this cannot predict effects in a body.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: PNC-27 induces tumor cell lysis as the intact peptide (2010) ↗ · PNC-27 binds HDM-2 and induces membrane-pore formation (2022) ↗

Safety & what remains unknown

Human safety is unknown. A membrane-disrupting peptide could harm normal tissue under real-world conditions, and research-grade products are not manufactured or tested as medicines.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Evidence boundaries

One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This profile covers preclinical cancer biology. No completed human trials of PNC-27 were found when this page was checked. PepsRadar does not link to sellers from this page: people with cancer should rely on their oncology team, and research listings are not treatments.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

No seller links for this compound

This is an experimental compound without human treatment evidence. PepsRadar does not link to research listings as treatments.

Biology & proposed mechanism

Investigators report that PNC-27 binds HDM-2 found on the membranes of some cancer cells and forms pores that rupture them, while sparing non-cancer cells in the same experiments. These are laboratory observations about cell membranes, not evidence of tumor control in patients.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Questions worth asking

  • Is PNC-27 a cancer treatment?
  • What material, population, and route were actually studied?
  • One pair of cell lines in culture cannot predict effects in a body, where delivery, breakdown, immune reactions and tumor variety matter. Most PNC-27 studies come from one research group, and no human efficacy or safety data exist.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is PNC-27 a cancer treatment?

No. It is an experimental molecule studied in cell cultures and animals. It has not been shown to treat cancer in people and should never replace care from an oncology team.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide · 2010 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections